ClinicalTrials.gg
Not yet recruitingNCT07618156Updated Jun 1, 2026

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy Volunteers

A Phase 1 interventional study of KR25102 for Injection and Placebo for KR25102 for Injection in Healthy Volunteers (HV), sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Phase 1 Single Ascending Doses(SAD): Six cohorts of 53 healthy volunteers (HVs) will receive a single IV bolus injection of study drug or placebo.

Phase 1 Multiple Ascending Doses(MAD): Three cohorts of 30 HVs will receive multiple IV bolus injections of study drug or placebo every day. After 7 days of continuous administration, the safety, tolerance and Pharmacokinetic/Pharmacodynamic characteristics of multiple administrations were evaluated.

Read the detailed description

This study adopts a single-center, randomized, double-blind, placebo-controlled parallel-group, dose-escalation design.

This single ascending dose (SAD) study is designed with six dose cohorts: 5 mg, 10 mg, 20 mg, 30 mg, 45 mg, and 60 mg. A total of 53 healthy adult participants are planned to be enrolled.

Three participants are planned for the 5 mg cohort, randomized in a 2:1 ratio of investigational product to placebo. Each of the remaining five dose cohorts will enroll 10 participants, randomized in an 8:2 ratio of investigational product to placebo.

For the multiple ascending dose (MAD) part, three dose cohorts (10 mg, 20 mg, and 30 mg) are planned. A total of 30 healthy adult participants will be enrolled, with 10 participants per cohort randomized in an 8:2 ratio of investigational product to placebo.Subjects will receive once daily administration for 7 consecutive days according to the randomization scheme.

02

Conditions studied

  • Healthy Volunteers (HV)

Keywords

  • KR25102, Pharmacokinetics, Safety
03

In context

Lead sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged between 18 and 55 years inclusive (as of the time of signing the form);
  2. Male participants with body weight ≥ 50 kg and female participants with body weight ≥ 45 kg, with a (BMI) ranging from 19 to 26 kg/m² (inclusive of boundary values);
  3. Participants and their partners have no plans for conception, sperm donation or oocyte donation from signing the informed consent form until 2 months after the last dose of study drug, and are willing to adopt highly effective measures;
  4. Female participants: not pregnant or breastfeeding; female participants of must have negative serum pregnancy test results at screening and baseline visits;
  5. For groups requiring pain testing: willing to undergo pain tests and pass training; with no wounds or skin diseases on the skin at the pain-stimulated site;
  6. Participants fully understand the purpose, requirements and potential risks of this trial, are willing to strictly comply with all trial requirements, voluntarily participate in the clinical trial and sign the written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with previous or current clinical acute or chronic diseases including but not limited to cardiovascular, endocrine-metabolic, neuropsychiatric, digestive, respiratory, hematopoietic-lymphoid, immune, urinary, musculoskeletal diseases and malignant tumors, who are judged unsuitable for enrollment by the investigator;
  2. Subjects with personal or family history of hereditary angioedema;
  3. Subjects who have undergone major surgery within 6 months prior to screening, or plan to receive surgical operations during the trial;
  4. Subjects who have taken any medicines or health supplements (including Chinese herbal medicines) within 14 days before dosing; or those who are known to require other drug treatments during the trial at screening.
  5. Subjects who have used any hepatic enzyme inhibitors/inducers within 1 month before dosing (inhibitors such as itraconazole, clarithromycin, ketoconazole, ritonavir, nelfinavir, cobicistat, telithromycin or nefazodone; inducers such as carbamazepine, phenytoin, phenobarbital, St. John's wort, etc.).
  6. Subjects who have participated in any clinical trials with drugs/devices within 3 months prior to screening, or plan to participate in other clinical trials during the study.
  7. Subjects with a history of drug abuse or positive results in drug abuse screening;
  8. Subjects with abnormal physical examination results at screening or baseline as judged by the investigator;
  9. Subjects with positive screening results for surface antigen, virus antibody, antibody or treponema pallidum antibody;
  10. Subjects with cardiac diseases including but not limited to congenital long syndrome, torsades de pointes or risk factors for torsades de pointes (e.g., cardiac insufficiency, family history of long QT syndrome), those currently receiving Class IA anti-arrhythmic drugs (e.g., quinidine or procainamide), Class III anti-arrhythmic drugs (e.g., amiodarone or sotalol) or other drugs known to affect QT interval, or those with Fridericia-corrected QT interval (QTcF) ≥ 450 ms (male), QTcF ≥ 460 ms (female), PR interval > 200 ms or QRS interval ≥ 120 ms at screening;
  11. Subjects who fail pain test training as judged by the investigator (only applicable to groups requiring pain testing).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    Investigational Product (KR25102 for Injection)

    Single-ascending-dose (5 mg, 10 mg, 20 mg, 30 mg, 45 mg, 60 mg) and multiple-ascending-dose (10 mg, 20 mg, 30 mg) intravenous administration of KR25102 for Injection.

    Drug: KR25102 for Injection

  • Placebo comparator
    Placebo

    Matching placebo for KR25102 for Injection, administered intravenously.

    Drug: Placebo for KR25102 for Injection

Interventions

  • DrugKR25102 for Injection

    Intravenous injection of KR25102 for Injection at different dose levels in SAD and MAD cohorts.

  • DrugPlacebo for KR25102 for Injection

    Intravenous injection of matching placebo.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    including vital signs, physical examination (neurological examination and injection-site examination included), 12-lead electrocardiogram, laboratory tests, abdominal ultrasonography, etc.

    Time frame: From study drug administration to 15 days after the last dose

Secondary outcomes

  1. Single-Dose Pharmacokinetic (PK) Parameters

    AUC₀-ₜ

    Time frame: From study drug administration to 120 hours after single dose administration

  2. Single-Dose Pharmacokinetic (PK) Parameters

    AUC₀-inf

    Time frame: From study drug administration to 120 hours after single dose administration

  3. Single-Dose Pharmacokinetic (PK) Parameters

    Tmax

    Time frame: From study drug administration to 120 hours after single dose administration

  4. Single-Dose Pharmacokinetic (PK) Parameters

    Tlag

    Time frame: From study drug administration to 120 hours after single dose administration

  5. Single-Dose Pharmacokinetic (PK) Parameters

    Cmax

    Time frame: From study drug administration to 120 hours after single dose administration

  6. Single-Dose Pharmacokinetic (PK) Parameters

    t1/2

    Time frame: From study drug administration to 120 hours after single dose administration

  7. Multiple-dose Pharmacokinetic (PK) Parameters

    Cmin,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  8. Multiple-dose Pharmacokinetic (PK) Parameters

    Ctrough

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  9. Multiple-dose Pharmacokinetic (PK) Parameters

    Cmax,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  10. Multiple-dose Pharmacokinetic (PK) Parameters

    Cav,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  11. Multiple-dose Pharmacokinetic (PK) Parameters

    AUCtau,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  12. Multiple-dose Pharmacokinetic (PK) Parameters

    CLss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  13. Multiple-dose Pharmacokinetic (PK) Parameters

    Tmax,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  14. Multiple-dose Pharmacokinetic (PK) Parameters

    t1/2,ss

    Time frame: From multiple-dose administration to 120 hours after the 7th dose

  15. QTcF Interval Changes and Correlation With Plasma Drug Concentration

    Changes in QTcF interval relative to baseline (ΔQTcF), changes relative to placebo (ΔΔQTcF)

    Time frame: From study drug administration to 24 hours after dosing

  16. QTcF Interval Changes and Correlation With Plasma Drug Concentration

    changes relative to placebo (ΔΔQTcF)

    Time frame: From study drug administration to 24 hours after dosing

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to commercial confidentiality and privacy protection requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 1, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618156
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Man Xu
Contact
xuman@kvvit.com
+86-19979703650
Guoping Yang
principal investigator · The Third Xiangya Hospital, Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion